Abe Sarah Krull, Inoue Manami, Sawada Norie, Iwasaki Motoki, Shimazu Taichi, Yamaji Taiki, Sasazuki Shizuka, Tanaka Yasuhito, Mizokami Masashi, Tsugane Shoichiro
Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Epidemiology and Prevention Group, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan.
Cancer Epidemiol. 2015 Aug;39(4):562-6. doi: 10.1016/j.canep.2015.06.002. Epub 2015 Jul 3.
Several studies have assessed the association between hepatitis B virus (HBV) and hepatitis C virus (HCV) and non-Hodgkin's lymphoma. However, few studies are cohort by design, conducted within the Asian context and even fewer studies consider other lymphoid malignancies. The aim of this study was to assess the association between HBV and HCV and the risk of lymphoid malignancies among Japanese adults.
The Japan Public Health Center prospective-based Study Cohort II was initiated in 1993/1994. 20,360 subjects with available data on HBV and HCV infection status from blood samples were followed up until the end of 2010 for an average of 16 years. During 324,139 person-years, 120 newly diagnosed cases of lymphoid malignancies were identified. Cox proportional hazards models were employed to calculate hazard ratios (HRs) and 95% confidence intervals (95%CIs).
Of 20,360 subjects, 508 were HBsAg positive, 11,035 were anti-HBc positive, and 1,129 subjects were anti-HCV positive at baseline. The presence of HBsAg was positively associated with malignant lymphoma, especially with non-Hodgkin's lymphoma (HR=3.56, 95%CI=1.37-9.18) and diffuse large B-cell lymphoma (HR=7.22, 95%CI=2.34-22.29). In contrast, no clear association was observed between the presence of anti-HBc and anti-HCV.
In conclusion, HBsAg but not anti-HBc or anti-HCV was positively associated with malignant lymphoma, particularly non-Hodgkin's lymphoma and diffuse large B-cell lymphoma in Japanese adults.
多项研究评估了乙型肝炎病毒（HBV）和丙型肝炎病毒（HCV）与非霍奇金淋巴瘤之间的关联。然而，很少有研究采用队列设计，在亚洲背景下开展，且考虑其他淋巴系统恶性肿瘤的研究更少。本研究旨在评估HBV和HCV与日本成年人淋巴系统恶性肿瘤风险之间的关联。
日本公共卫生中心前瞻性队列研究II于1993/1994年启动。对20360名有血液样本中HBV和HCV感染状态可用数据的受试者进行随访，直至2010年底，平均随访16年。在324139人年期间，共确定了120例新诊断的淋巴系统恶性肿瘤病例。采用Cox比例风险模型计算风险比（HRs）和95%置信区间（95%CIs）。
在20360名受试者中，基线时508人HBsAg阳性，11035人抗-HBc阳性，1129人抗-HCV阳性。HBsAg的存在与恶性淋巴瘤呈正相关，尤其是与非霍奇金淋巴瘤（HR=3.56，95%CI=1.37-9.18）和弥漫性大B细胞淋巴瘤（HR=7.22，95%CI=2.34-22.29）。相比之下，未观察到抗-HBc和抗-HCV的存在之间有明显关联。
总之，在日本成年人中，HBsAg而非抗-HBc或抗-HCV与恶性淋巴瘤呈正相关，尤其是非霍奇金淋巴瘤和弥漫性大B细胞淋巴瘤。
